Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 169-189 , March 2006

Risks and side effects of therapy with plasma and plasma fractions

  • Sheila MacLennan, MBBS, FRCP FRCPath (Consultant in Transfusion Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 113 2148 638; Fax: +44 113 2148 696.
  • John A.J. Barbara, MA, MSc, PhD, FIBiol, FRCPath (Microbiology Consultant to the National Blood Service)

References 

  1. In: Handbook of Transfusion Medicine. Norwich: The Stationery Office; 2001;
  2. Williamson LM, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang. 1995;69(3):159–165
  3. Domen RE, Hoeltge GA. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med. 2003;127(3):316–320
  4. Vamvakas EC, Pineda AA. Allergic and anaphylactic reactions. In:  Popovsky MA editors. Transfusion Reactions. Bethesda: AABB Press; 2001;p. 83–127
  5. Stainsby D, Cohen H, Jones H et al. Serious Hazards of Transfusion (SHOT) Annual Report 2003. Manchester Blood Centre: Serious Hazards of Transfusion Office; 2004.
  6. Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion. 1975;15(1):10–15
  7. Bochner BS, Lichtenstein LM. Anaphylaxis. N Engl J Med. 1991;324(25):1785–1790
  8. Koda Y, Watanabe Y, Soejima M, et al. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood. 2000;95(4):1138–1143
  9. Sharon R, Kidroni G, Michel J. Presence of aspirin in blood units. Vox Sang. 1980;38(5):284–287
  10. Poothullil J, Shimizu A, Day RP, Dolovich J. Anaphylaxis from the product(s) of ethylene oxide gas. Ann Intern Med. 1975;82(1):58–60
  11. Soetens FM. Anaphylaxis during anaesthesia: diagnosis and treatment. Acta Anaesthesiol Belg. 2004;55(3):229–237
  12. Sandler SG, Eckrich R, Malamut D, Mallory D. Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood. 1994;84(6):2031–2035
  13. Vyas GN, Perkins HA, Fudenberg HH. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet. 1968;2(7563):312–315
  14. Vyas GN, Fudenberg HH. Isoimmune anti-IgA causing anaphylactoid transfusion reactions. N Engl J Med. 1969;280(19):1073–1074
  15. Boralessa H. Investigation and clinical management of suspected reactions to IgA. NBS Clinical Policies Group, 2003. online at http://www.blood.co.uk/hospitals/guidelines/index.htm.
  16. Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have ‘high-titer’ anti-A/A,B: implications for transfusion policy. Transfusion. 2004;44(6):805–808
  17. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573–577
  18. Asher D, Atterbury CLJ, Chapman C et al. Serious Hazards of Transfusion Annual Report 2000–2001. Manchester: SHOT Steering Group, 2002.
  19. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454–462
  20. Popovsky MA, Davenport RD. Transfusion-related acute lung injury: femme fatale?. Transfusion. 2001;41(3):312–315
  21. MacLennan S, Lucas G, Brown C, et al. Prevalence of HLA and HNA antibodies in donors: correlation with pregnancy and transfusion history. Vox Sang. 2004;87(supplement 3):4
  22. Kopko PM, Holland PV. Transfusion-related acute lung injury. Br J Haematol. 1999;105(2):322–329
  23. O'Connor PC, Erskine JG, Pringle TH. Pulmonary oedema after transfusion with fresh frozen plasma. Br Med J (Clin Res Ed). 1981;282(6261):379–380
  24. Popovsky MA. Circulatory overload. In:  Popovsky MA editors. Transfusion Reactions. Bethesda: AABB Press; 2001;p. 255–260
  25. Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev. 1988;2(2):76–94
  26. Mollison PL, Engelfreit CP, Contreras M. Some unfavourable effects of transfusion. Blood Transfusion in Clinical Medicine. Oxford: Blackwell Scientific Publications; 1997;pp. 506–507
  27. Casewell MW, Slater NG, Cooper JE. Operating theatre water-baths as a cause of pseudomonas septicaemia. J Hosp Infect. 1981;2(3):237–247
  28. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study. N Engl J Med. 1996;334(26):1685–1690
  29. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993–2001. Vox Sang. 2003;84(4):274–286
  30. Barbara, JAJ. The rationale for pathogen-inactivated treatment of blood components. Int J Hematol 2004; 80: 311–316.
  31. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 2001;41(1):130–135
  32. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet. 2000;356(9234):999–1000
  33. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol. 2002;83(Pt 11):2897–2905
  34. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Lancet. 2004;363(9407):417–421
  35. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364(9433):527–529
  36. Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet. 2004;364(9433):529–531
  37. Bruce-Chwatt LJ. Blood transfusion and tropical disease. Trop Dis Bull. 1972;69(9):825–862
  38. Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion. 1991;31(6):547–557
  39. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion. 2003;43(9):1322–1329
  40. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol. 2000;109(4):680–693
  41. Guidelines for the Blood Transfusion Services in the United Kingdom. 6th edn. Norwich: The Stationery Office; 2002;
  42. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41(12):1548–1552
  43. Simonsen AC, Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma. A randomised crossover trial in 12 healthy human volunteers. Vox Sang. 1999;77(4):210–217
  44. Pinkoski L, Smyers J, Corash L, et al. Pathogen inactivation of plasma using Helinx technology conserves the activity of coagulation, anticoagulation and fibrinolytic proteins. Blood. 2001;98(supplement):541a
  45. Corbin F. In: Monograph on COBE BCT Pathogen Inactivation Technology. 1999;
  46. Corbin F. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol. 2002;76(supplement 2):253–257
  47. Hornsey VS, Young DA, Docherty A, et al. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Transfus Med. 2004;14(5):369–374
  48. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion. 2003;43(10):1481–1492
  49. Mohr H, Knuver-Hopf J, Lambrecht B, et al. No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Hematol. 1992;65(5):224–228
  50. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT blood system. Vox Sang. 2003;85(3):171–182
  51. Harrison CN, Lawrie AS, Iqbal A, et al. Plasma exchange with solvent–detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol. 1996;94(4):756–758
  52. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?. J Clin Apheresis. 2000;15(3):169–172
  53. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121(5):778–785
  54. Baudoux E, Margraff U, Coenen A, et al. Hemovigilance: clinical tolerance of solvent–detergent treated plasma. Vox Sang. 1998;74(supplement 1):237–239
  55. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999;21(3):171–185
  56. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241–251
  57. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology. 1996;47(3):674–677
  58. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(6 supplement 5):S2–S8
  59. Greenbaum BH. Differences in immunoglobulin preparations for intravenous use: a comparison of six products. Am J Pediatr Hematol Oncol. 1990;12(4):490–496
  60. Ember JA, Jagels MA, Hugli TE. Characterisation of Complement Anaphylatoxins and their Biological Responses. The Human Complement System in Health and Disease. New York: Marcel Dekker; 1998;pp. 83–118
  61. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion. 2001;41(2):264–268
  62. Gottlieb S. Intravenous immunoglobulin increases risk of thrombotic events. BMJ. 2002;324(7345):1056
  63. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. 1993;50(2):137–139
  64. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy. 1995;15(6):765–772
  65. Perazella MA, Cayco AV. Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise?. Am J Ther. 1998;5(6):399–403
  66. Epstein J, Gaines A, Kapit R, et al. In: FDA Medical Bulletin  editors. Important Drug Information: Immune Globulin Intravenous. 1999;Online. Available at: http://www.fda.gov/medbull/summer99/Globulin.html
  67. Molina JM, Coffineau A, Rain JD, et al. Aseptic meningitis following administration of intravenous immune globulin. Clin Infect Dis. 1992;15(3):564–565
  68. Vera-Ramirez M, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1992;42(8):1636–1637
  69. Ozsoylu S. Aseptic meningitis and intravenous gammaglobulin treatment. Am J Dis Child. 1993;147(2):129–130
  70. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121(4):259–262
  71. Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr. 1997;130(2):281–283
  72. Ben Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med. 1992;326(4):270–271
  73. Berkovitch M, Dolinski G, Tauber T, et al. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol. 1999;21(6):411–415
  74. Thomas MJ, Misbah SA, Chapel HM, et al. Hemolysis after high-dose intravenous Ig. Blood. 1993;82(12):3789
  75. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion. 1986;26(5):410–412
  76. Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion. 1986;26(2):210–213
  77. Lever AM, Webster AD, Brown D, Thomas HC. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet. 1984;2(8411):1062–1064
  78. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994;331(24):1607–1611
  79. Bjorkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988;84(1):107–111
  80. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med. 1994;331(24):1649–1650
  81. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang. 2000;78(2):86–95
  82. Vermylen J. Complications to infusion therapy. In:  Brinkhous KM,  Hemker HC editor. Handbook of Hemophilia. Amsterdam: Excerpta Medica; 1975;
  83. Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol. 1999;104(4):909–914
  84. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–435
  85. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost. 2004;2(7):1047–1054
  86. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80(6):912–918
  87. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis. 1998;9(supplement 1):S115–S118
  88. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA study group. Factor eight bypassing activity. Thromb Haemost. 1997;77(6):1113–1119
  89. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(supplement 1):S13–S17
  90. Roberts HR, Bingham MD. Other coagulation factor deficiencies. In:  Loscalzo J,  Schafer AI editor. Thrombosis and Haemorrhage. Baltimore: Williams & Wilkins; 1998;p. 773–802
  91. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane injuries group albumin reviewers. BMJ. 1998;317(7153):235–240
  92. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–2256
  93. Dzik W, Rao A. Why do physicians request fresh frozen plasma?. Transfusion. 2004;44(9):1393–1394
  94. Cardigan R, Prowse CV, Williamson LM. Leucocyte depletion and pathogen inactivation. In Barbara JAJ, Regan F, Contreras MC (ed.) Transfusion Microbiology. Cambridge: Cambridge University Press; in press.

PII: S1521-6926(05)00034-4

doi: 10.1016/j.beha.2005.01.033

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 169-189 , March 2006

Article Tools

* Image Usage & Resolution